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 Introduction
Cardioplegia is fundamental to the intracardiac repair 
of congenital heart defects. In combination with hypo-
thermia, it remains the mainstay of myocardial protec-
tion against ischaemia-reperfusion injury during 
cardiac surgery, providing access to a still and bloodless 
field through electromechanical arrest.1 However, the 
ubiquitous release of troponin following aortic cross-
clamping in children demonstrates that myocardial 
injury is a routine occurrence.2,3 Low cardiac output 
syndrome remains the most common premorbid com-
plication after cardiac surgery in children and the most 
frequent seminal event leading to death.4 As current 
cardioplegia techniques were mostly derived from adult 
or laboratory models, they may not provide optimal 
protection for the immature myocardium.5–7
Recent surveys of practice have shown marked varia-
tions in the use of commercially-available and customised 
cardioplegia solutions in children in North America8 and 
worldwide.9 This may be driven by a lack of evidence to 
support one technique over another; the paediatric car-
diac surgery literature contains no late phase, randomised, 
controlled trials and there is a need for high-quality evi-
dence to guide practice and improve outcomes.10 We, 
therefore, conducted a survey to establish the current car-
dioplegia practice in paediatric cardiac surgery in the UK 
& Ireland and the willingness of surgeons to randomise 
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Abstract
Introduction: Many techniques are available for cardioplegic arrest in children, but there is a lack of late phase clinical trials 
to guide practice. We surveyed paediatric cardiac surgeons and perfusionists to establish current practice and willingness 
to change within a clinical trial.
Methods: An online survey was sent to all consultant paediatric cardiac surgeons and chief perfusionists in paediatric 
centres in the UK and Ireland. Information was sought on cardioplegia type, composition, temperature, topical cooling, 
dosing for induction and maintenance, interval between doses, whether practice changed with patient age or complexity 
and whether respondents would be willing and able to use different cardioplegia solutions within a randomised trial.
Results: Responses were obtained from 32 (78.0%) surgeons and 12 (100%) perfusionists. Twenty-seven (84.4%) surgeons 
use blood cardioplegia in infants, with St. Thomas’ Harefield preparation the most popular (19, 59.4%), used routinely in 
eight (66.7%) centres. Twenty-two (68.8%) administer at 4-6°C, 18 (56.3%) use topical cooling, 18 (56.3%) give 30 ml/kg 
induction and 15 ml/kg maintenance, with 23 (71.9%) re-dosing every 20-25 minutes. Thirty (93.8%) surgeons were open 
to randomising patients in a trial, with del Nido (29, 90.6%) the most popular.
Conclusions: This survey demonstrates heterogeneity in cardioplegia practice. Whilst most surgeons use blood cardioplegia, 
there is variation in type, temperature, topical cooling, dosing and intervals. Combined with a lack of evidence from late 
phase trials, our findings support the presence of clinical equipoise. Surgeons are willing to change practice, suggesting 
that a pragmatic, multi-centre, randomised, controlled trial of cardioplegia in children is feasible.
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patients to different solutions within the context of a 
multi-centre, randomised, controlled trial.
Methods
A survey link was sent via email to all 41 consultant pae-
diatric cardiac surgeons and the chief perfusionist 
(identified via The Society of Clinical Perfusion 
Scientists) at each of the 12 centres performing chil-
dren’s heart surgery in the United Kingdom and the 
Republic of Ireland in December 2017. Non-responders 
received a second personalised follow-up email in 
January 2018 to prompt completion. Respondents were 
required to provide consent for anonymous reporting of 
the information provided. The survey data were col-
lected and managed using the REDCap electronic data 
capture tools run by the Birmingham Surgical Trials 
Consortium at the University of Birmingham, under 
licence from Vanderbilt University.11
The study design was informed by the Congenital 
Heart Surgeons’ Society survey of Kotani et al.8 A full list 
of questions is available as supplementary material. In 
brief, data was requested from each respondent for their 
current/usual cardioplegia practice in infants (30 days-1 
year), including type of solution, composition, tempera-
ture, topical cooling, dosing for induction and mainte-
nance and interval between doses. Respondents were 
asked whether their practice differs by patient age (neo-
nates, children over 1 year) and expected complexity of 
the repair and to provide details. Perfusionists were also 
asked for details of their cardioplegia-delivery system 
and whether any additional equipment or disposables 
would be required for other cardioplegia types.
Finally, respondents were asked whether they would 
be willing to use different types of cardioplegia within 
the context of a clinical trial, specifically: del Nido car-
dioplegia, as used at Boston Children’s Hospital;12 
Custodiol HTK (Dr Franz Köhler Chemie, Bensheim, 
Germany); St. Thomas’ blood Harefield preparation 
(Terumo BCT, Larne, UK); or St. Thomas’ Hospital 
crystalloid solution No. 2 (Plegisol, Abbott Laboratories, 
Chicago, IL). If so, they were asked whether there are 
any patient groups in whom they would not be willing 
to randomise to each solution and what interval between 
doses would be acceptable, assuming no electrome-
chanical activity; if not, they were asked to describe 
their concerns over using that solution.
Statistical analysis was performed using Excel 
(Microsoft Corporation, Redmond, WA). Categorical 
data were expressed as counts and percentages. The cor-
responding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
The survey was completed by 44 of 52 (84.6%) health-
care professionals contacted, 32 of 41 (78.0%) consul-
tant surgeons and all 12 (100%) chief perfusionists.
Of the 32 surgeons who responded, 27 (84.4%) use 
blood cardioplegia in infants, with St. Thomas’ Harefield 
preparation in a 4:1 blood-to-crystalloid ratio being the 
most popular (19, 59.4%) and used routinely in eight 
(66.7%) centres (Figure 1). Five (15.6%) surgeons from 
two centres use bespoke institutional depolarising blood 
cardioplegia solutions; no centres currently use del Nido 
Figure 1. Types of cardioplegia solution used in infants.
Drury et al. 3
solution as it has not been available commercially in the 
UK or Ireland. Two (6.3%) surgeons who use blood car-
dioplegia in older children switch to crystalloid cardio-
plegia in neonates; conversely, three (9.4%) surgeons 
who use crystalloid in infants change to blood in older 
children. No surgeons make significant changes to their 
cardioplegia strategy depending on the expected com-
plexity of the repair alone.
Variations in the techniques of surgeons responding 
to the survey are shown in Table 1. The preferred tem-
perature of administration is 4-6°C for 22 (68.8%) sur-
geons, whether using a blood or crystalloid solution; 
additional topical cooling of the heart is employed rou-
tinely by 14 (43.8%) and selectively by four (12.5%), 
with only one (3.1%) considering giving a warm termi-
nal ‘hot shot’ dose in long cross-clamp times. All sur-
geons administer antegrade cardioplegia, with two 
(6.3%) using a combined antegrade and retrograde 
approach in selected cases. The majority (18, 56.3%) 
give an induction dose of 30 ml/kg and maintenance of 
15 ml/kg, with six (18.8%) opting for an induction of 
20-25 ml/kg and maintenance of 10 ml/kg. The usual/
preferred interval between doses is every 20-25 minutes 
for 23 (71.9%) and 30-35 minutes for eight (25.0%). The 
main indication for re-dosing is time elapsed (28, 
87.5%), even in the absence of overt electromechanical 
activity; one surgeon (3.1%) uses a single dose unless 
cardiac activity becomes disruptive to the repair.
In all centres, cardioplegia is administered by the 
perfusionist, using a roller pump although, in one cen-
tre, crystalloid cardioplegia is given by the anaesthetist, 
using a handheld syringe/pressure bag, when required. 
A single-pass system is used by eight (66.7%) centres, 
recirculating by one (8.3%) and either, depending on the 
cardioplegia type, by one (8.3%). Perfusionists reported 
that no additional equipment other than disposables 
would be required to deliver alternative cardioplegia 
types at every centre.
Within the context of a clinical trial, 29 (90.6%) sur-
geons were willing to randomise to del Nido cardiople-
gia; of these, concerns were raised by five (17.2%) 
regarding patients with an expected short aortic cross-
clamp time, such as atrial or ventricular septal defect 
repair, by four (13.8%) for use in neonates and by two 
(6.9%) for those in whom the need to re-clamp the aorta 
was anticipated. The acceptable interval between doses 
with del Nido cardioplegia, assuming no electrome-
chanical activity, was up to 60 minutes for 17 (58.6%) 
surgeons, up to 90 minutes for 10 (34.5%) and up to 120 
minutes for one (3.4%), with one not responding. 
Unsurprisingly, St. Thomas’ Harefield preparation was 
acceptable to 24 (75.0%) surgeons, most of whom cur-
rently use it routinely; two (6.3%) others expressed con-
cern over its use in neonates due to its higher viscosity. 
St. Thomas’ Hospital crystalloid solution No. 2 (20, 
62.5%) and Custodiol HTK (19, 59.3%) were less popu-
lar, with concerns raised over the volume of crystalloid 
required, perceived inferior myocardial protection and 
that both would constitute a ‘backwards step’ from 
blood cardioplegia. The greatest combined acceptability 
was for St. Thomas’ Harefield preparation and del Nido 
solution, with 24 (75.0%) surgeons from 11 of the 12 
centres willing to randomise patients to either option 
(Table 2). Only two (6.3%) respondents were not open 
to changing their practice within a trial setting.
Table 1. Variations in the techniques used by responding 
surgeons (n=32).
Characteristic n (%)
Temperature of cardioplegia
 <4°C 2 (6.3%)
 4-6°C 22 (68.8%)
 7-9°C 5 (15.6%)
 10-12°C 1 (3.1%)
 >12°C 2 (6.3%)
Topical cooling of heart
 Routine 14 (43.8%)
 Selective 4 (12.5%)
 No 14 (43.8%)
Terminal warm dose ‘hot shot’
 No 31 (96.9%)
 Selected cases 1 (3.1%)
Route of delivery
 Antegrade only 30 (93.8%)
 Combined in selected cases 2 (6.3%)
Change practice by patient age
 No change 27 (84.4%)
 Switch to crystalloid in neonate 2 (6.3%)
 Switch to blood in older child 3 (9.4%)
Induction dose
 10 ml/kg 1 (3.1%)
 20 ml/kg 7 (21.9%)
 25 ml/kg 2 (6.3%)
 30 ml/kg 18 (56.3%)
 Determined by BSA 4 (12.5%)
Maintenance dose
 ⩽10 ml/kg 2 (6.3%)
 15 ml/kg 6 (18.8%)
 20 ml/kg 18 (56.3%)
 25 ml/kg 2 (6.3%)
 Determined by BSA 4 (12.5%)
Indication for maintenance dose
 Time since last dose 28 (87.5%)
 Electromechanical activity 1 (3.1%)
 Depends on case / other 3 (9.4%)
Interval between doses
 20-25 minutes 23 (71.9%)
 30-35 minutes 8 (25.0%)
 Usually single dose 1 (3.1%)
BSA: body surface area.
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Discussion
In this survey of current paediatric cardioplegia practice 
in the UK and Ireland, we identified variations in prac-
tice, although the majority use a similar strategy of ante-
grade cold blood cardioplegia with a few adjustments 
for patient age or anticipated length of ischaemia and 
frequent re-dosing based on time since last dose. 
However, most surgeons are not devoted to one 
approach, with widespread willingness to change prac-
tice and randomise patients within a clinical trial, per-
haps because the optimal solution for paediatric 
myocardial protection is not established.
Previous surveys of practice have described varia-
tions in the application of cardioplegia solutions in chil-
dren in other healthcare systems. Kotani and colleagues 
collected data from 56 members of the Congenital Heart 
Surgeons’ Society in North America and found marked 
variation in the type of cardioplegia used.8 Whilst blood-
based cardioplegia was preferred by 86% of respond-
ents, with del Nido solution (38%) the most popular, the 
next most frequent was ‘other’ (34%), custom-mixed 
solutions unique to an individual centre. On the other 
hand, there was consistency in the use of cold (⩽10°C) 
cardioplegia (93%), an exclusively antegrade route of 
administration (89%) and, to a lesser extent, topical 
cooling of the myocardium (64%). Harvey and col-
leagues surveyed 146 paediatric centres across 5 conti-
nents, finding similar variation in the types of 
cardioplegia used; whilst depolarising solutions were 
predominant, 32% of North American centres routinely 
used del Nido solution and 31% of European centres 
used Custodiol HTK.9 Finally, in an earlier survey from 
Japan, Itoh and colleagues reported that 58% of centres 
used exclusively crystalloid cardioplegia, 32% used only 
blood and 10% used both, with 70% giving the cardio-
plegia at or below 10°C.13
Widespread variations in care suggest a lack of defin-
itive evidence to support one technique over another. 
Randomised, controlled trials represent the gold stand-
ard in evaluating healthcare interventions through rig-
orous testing of a predefined protocol and minimisation 
of bias.14 In a recent systematic review, we identified 26 
clinical trials of cardioplegia in paediatric cardiac sur-
gery in the published literature; however, these were 
exclusively small, single-centre, phase II trials of low 
value, uncertain quality and at risk of systematic bias.10 
The heterogeneity of patients, interventions and 
reported outcome measures across trials also precluded 
the pooling of results for meta-analysis. Furthermore, 
these trials included very few neonates, a high-risk 
cohort in whom myocardial metabolism and cellular 
homeostasis differ from the more mature heart and the 
protective effects of cardioplegia are less well under-
stood.3
The lack of evidence from late phase clinical trials to 
support clinical decision-making on cardioplegia in 
children, combined with the widespread variability in 
practice demonstrated in this study, suggest clinical 
equipoise. This is confirmed by the willingness of almost 
all respondents to change their practice and supports 
the feasibility of a multi-centre clinical trial. Such a trial 
would need to be pragmatic, considering the variations 
in practice and concerns raised in the survey by poten-
tial collaborators, to maximise participation and make 
the findings applicable to routine clinical practice. It 
would require clinically important endpoints that, if 
positive, would be convincing to the wider community 
and, thereby, have the potential to change practice. 
These should include both validated early outcomes to 
have contemporary impact and the long-term func-
tional outcomes that are most important to patients and 
their families.
The strengths of this study include the high response 
rate and completeness of answers, including surgeons 
and perfusionists from all centres in the UK and Ireland. 
Limitations include the applicability of our findings to 
other countries and the inability to determine whether 
the variations in practice described have any impact on 
patient outcomes. Whilst few respondents changed their 
strategy due to the age of the child or complexity of the 
repair, the impact of other factors, such as cyanosis or 
ventricular hypertrophy, on decision-making was not 
explicitly sought.
In conclusion, this survey of current cardioplegia 
practice in paediatric cardiac surgery in the UK and 
Ireland demonstrates heterogeneity in the care provided 
to children, according to their surgeon and centre. As 
shown in previous studies,8,9 whilst most surgeons now 
use blood cardioplegia, there is variation in the type of 
Table 2. Willingness of responding surgeons to use different 
types of cardioplegia within a clinical trial (n=32).
Cardioplegia types n (%)
Individual solutions
 del Nido 29 (90.6%)
 St. Thomas’ blood (Harefield preparation) 24 (75.0%)
 St. Thomas’ Hospital crystalloid No. 2 20 (62.5%)
 Custodiol HTK 19 (59.3%)
Combinations
 del Nido + St. Thomas’ (Harefield) 24 (75.0%)
 del Nido + St. Thomas’ crystalloid No. 2 18 (56.3%)
 del Nido + Custodiol HTK 18 (56.3%)
 St. Thomas’ (Harefield) + St. Thomas crystal-
loid No. 2
17 (53.1%)
 St. Thomas’ (Harefield) + Custodiol HTK 14 (43.8%)
 St. Thomas crystalloid No. 2 + Custodiol HTK 13 (40.6%)
Not willing to change practice  2 (6.3%)
HTK: histidine-tryptophan-ketoglutarate.
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solution, temperature, use of topical cooling, dosing and 
intervals between doses. In combination with the lack of 
evidence from late phase clinical trials,10 our findings 
support the presence of clinical equipoise. Indeed, the 
surgeons’ willingness to change practice within a clini-
cal trial suggests that a pragmatic, multi-centre, ran-
domised, controlled trial of del Nido solution versus St. 
Thomas’ blood cardioplegia in children is feasible.
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